Ablavar

(GADOFOSVESET TRISODIUM in)

ApprovedSmall molecule

LLantheus Medical Imaging

Ablavar is one of 83 small molecule programs targeting Breast Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Ovarian CancerWithdrawn

Breast CancerPreclinical

Active, not recruiting

Ovarian CancerApproved

Withdrawn

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Ablavar

LLantheus Medical Imaging

Approved

2 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Nodal Staging in Breast Cancer With MRL

Terminated·MMaastricht University Medical Center·N/A·NCT01609920·97 enrolled

Gadofosveset for Axillary Staging in Breast Cancer Patients

Completed·MMaastricht University Medical Center·N/A·NCT01437865·10 enrolled

Ovarian Cancer1 trial

Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer

Withdrawn·MMaastricht University Medical Center·Phase 4·NCT02243059

Imaging Techniques1 trial

Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer

Completed·MMaastricht University Medical Center··NCT01721785·307 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 22, 2008

ABLAVAR

NDA NDA021711

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for GADOFOSVESET TRISODIUM in. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GADOFOSVESET TRISODIUM in compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GADOFOSVESET TRISODIUM in. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021711). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Lantheus Medical Imaging company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: LLantheus Medical Imaging

Ablavar

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer2 trials

Ovarian Cancer1 trial

Imaging Techniques1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News